ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Regístrate

¿Ya eres miembro? Iniciar sesión

Los Principales Corredores en Línea

Más Corredores en Línea

Datos
Noticias
Herramientas
Mercados
Descubrir

Hot Features

Follow Feed

Conéctese con traders e inversores en nuestra comunidad Follow Feed.

Flujo de Opciones

Explora datos de opciones completos y utiliza filtros avanzados con Options Flow.

Monitor

Organiza y monitorea tu lista de seguimiento de acciones y activos con Monitor.
Iniciar Sesión Premium IconPremium Help Menu
S&P 500
5,303.27
0.12%
Dow Jones
40,003.59
0.34%
US Dollar vs MXN
16.6086
-0.43%
Brent Oil
83.76
0.67%
Bitcoin
66,767.08
2.35%
Registration Strip Icon for alerts Regístrate para obtener alertas en tiempo real, cartera personalizada y movimientos del mercado.
Regístrate
  1. Inicio
  2. Invertir
  3. Acciones
  4. Estados Unidos
  5. NASDAQ
  6. Virax Biolabs Group Ltd (VRAX)

  7. Virax Biolabs Group Ltd (VRAX) Noticias

VRAX

Virax Biolabs (VRAX)

Virax Biolabs Group Ltd
Fecha:
Ordernar por:
 Showing the most relevant articles for your search:NASDAQ:VRAX
FechaHoraFuenteTítuloSímboloCompañía
25/04/202407:00PR Newswire (US)Virax Biolabs Launches Portfolio of Immune Profiling Solutions Evaluating Adaptive Immunity in Post-Viral Syndromes at ESCMID Global 2024NASDAQ:VRAXVirax Biolabs Group Ltd
16/04/202406:30PR Newswire (US)Virax Biolabs to Participate at ESCMID Global 2024NASDAQ:VRAXVirax Biolabs Group Ltd
15/03/202415:30PR Newswire (US)Virax Biolabs Announces Receipt of NASDAQ Notification Letter Regarding Minimum Bid Price DeficiencyNASDAQ:VRAXVirax Biolabs Group Ltd
22/01/202416:28Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:VRAXVirax Biolabs Group Ltd
22/01/202416:27Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:VRAXVirax Biolabs Group Ltd
21/12/202306:30PR Newswire (US)Virax Biolabs Forges Strategic Research Collaboration with University of Manchester and the Northern Care Alliance Foundation Trust to Enhance Understanding of Immune Responses in COVID PatientsNASDAQ:VRAXVirax Biolabs Group Ltd
20/12/202315:12Edgar (US Regulatory)Form 424B3 - Prospectus [Rule 424(b)(3)]NASDAQ:VRAXVirax Biolabs Group Ltd
18/12/202306:30PR Newswire (US)Virax Biolabs' CEO James Foster Issues Letter to ShareholdersNASDAQ:VRAXVirax Biolabs Group Ltd
17/12/202323:15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:VRAXVirax Biolabs Group Ltd
14/12/202306:30PR Newswire (US)Virax Biolabs Group Limited Announces 1-for-10 Share ConsolidationNASDAQ:VRAXVirax Biolabs Group Ltd
05/12/202315:06Edgar (US Regulatory)Form F-3 - Registration statement by foreign private issuersNASDAQ:VRAXVirax Biolabs Group Ltd
17/10/202315:05Edgar (US Regulatory)Form D - Notice of Exempt Offering of SecuritiesNASDAQ:VRAXVirax Biolabs Group Ltd
12/09/202306:30PR Newswire (US)Virax Biolabs Group Announces Early-Access Program Launch of Research Use Only ViraxImmune Product and Hosts WebinarNASDAQ:VRAXVirax Biolabs Group Ltd
01/09/202306:30PR Newswire (US)Virax Biolabs Group Appoints Dr. Nigel McCracken as Chief Operating Officer to Oversee Growth MomentumNASDAQ:VRAXVirax Biolabs Group Ltd
03/08/202306:30PR Newswire (US)Nasdaq Approves 180-Day Extension for Virax Biolabs Group to Meet Minimum $1 BidNASDAQ:VRAXVirax Biolabs Group Ltd
18/07/202306:30PR Newswire (US)Virax Biolabs Group Continues Growth and Expansion with the Addition of Research and Laboratory FacilitiesNASDAQ:VRAXVirax Biolabs Group Ltd
14/06/202315:32Edgar (US Regulatory)Annual and Transition Report (foreign Private Issuer) (20-f)NASDAQ:VRAXVirax Biolabs Group Ltd
14/06/202307:01Edgar (US Regulatory)Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)NASDAQ:VRAXVirax Biolabs Group Ltd
04/05/202306:30PR Newswire (US)Virax Biolabs Group Announces Establishment of Regional Headquarters at Dubai Science ParkNASDAQ:VRAXVirax Biolabs Group Ltd
19/04/202306:30PR Newswire (US)Virax Biolabs Group Limited Has Entered into an Agreement for the Distribution of Marburg Virus PCR Testing KitsNASDAQ:VRAXVirax Biolabs Group Ltd
31/03/202315:11Edgar (US Regulatory)Prospectus Filed Pursuant to Rule 424(b)(3) (424b3)NASDAQ:VRAXVirax Biolabs Group Ltd
31/03/202305:20Edgar (US Regulatory)Notice of Effectiveness (effect)NASDAQ:VRAXVirax Biolabs Group Ltd
22/03/202308:41Edgar (US Regulatory)Securities Registration (foreign Private Issuer) (f-1)NASDAQ:VRAXVirax Biolabs Group Ltd
15/03/202315:16Edgar (US Regulatory)Small Company Offering and Sale of Securities Without Registration (d)NASDAQ:VRAXVirax Biolabs Group Ltd
10/03/202316:17PR Newswire (US)Virax Biolabs Group Limited Announces Closing of $4 Million Private Placement Priced At-The-Market Under Nasdaq RulesNASDAQ:VRAXVirax Biolabs Group Ltd
08/03/202307:55PR Newswire (US)Virax Biolabs Group Limited Announces $4 Million Private Placement Priced At-The-Market Under Nasdaq RulesNASDAQ:VRAXVirax Biolabs Group Ltd
07/03/202306:30PR Newswire (US)Virax Biolabs Group Limited Introduces Avian Influenza A Virus Real-Time PCR Test KitNASDAQ:VRAXVirax Biolabs Group Ltd
07/02/202307:30PR Newswire (US)Virax Biolabs Group Limited Announces Purchase Order to Launch COVID-19 and Influenza A+B Antigen Combo Rapid Tests with Cosmos Health (NASDAQ:COSM)NASDAQ:VRAXVirax Biolabs Group Ltd
06/02/202315:05PR Newswire (US)Virax Biolabs to Present at the 2023 BIO CEO & Investor ConferenceNASDAQ:VRAXVirax Biolabs Group Ltd
04/01/202306:30PR Newswire (US)Virax Biolabs Introduces Human Papillomavirus ("HPV") Test KitNASDAQ:VRAXVirax Biolabs Group Ltd
 Showing the most relevant articles for your search:NASDAQ:VRAX

Su Consulta Reciente

AMEX
IEFN
iShares Evolved US Finan...
COIN
RBNETH
Ribbon
COIN
CRBNUSD
Carbon
COIN
PMGTUST
Perth Mint Gold Token
LSE
16DT
Anz Bank 42
ASX
RENT
Rent dot Com AU
BIT
W4LMJ1
UBS
Delayed Upgrade Clock
ADVFN Logo

México
Empresa
Negocios
Popular
Obtener la aplicación

Soporte: (55) 4170 8128 | soporte@advfn.mx

Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones

© 2024 ADVFN PLC - Todos los derechos reservados